I2 Pharmaceuticals, Inc.

Sea Lane Biotechnologies, LLC

Rigel Pharmaceuticals, Incorporated

Torch Therapeutics

Bioren, Inc.

Ramesh Bhatt

Lawrence C Horowitz

Arun K Kashyap

Todd M Kinsella

Li Xu

Aaron L Kurtzman

Michael D Horowitz

Kristen Baltgalvis

Donald G Payan

Wei Ey Li

Roberto Crea

Toshihiko Takeuchi

Pamela K Foreman

Randy Shen

Guido Cappuccilli

Charles H Hannum

Nurten Beyaz-Kavuncu

Phil Kobel

Takeuchi Toshihilo

Sihong Zhou

Ryann E O'Neil

Medini Gore

Danying Cai

Pamela Foreman

Lawrence Horowitz

Nurten Bayez

Guido Cappucilli

This invention describes the design of bispecific antibodies that function as conditionally effective therapeutics by binding to a functionally silent epitope on one component of a targeted signaling complex and simultaneously binding to a second protein, whose expression or accessibility is cell- or disease environment-specific, and whose antibody-driven proximity to the signaling complex leads to an alteration of signal transduction.

Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex

The present disclosure provides antibodies that specifically bind to and block signaling by ACVR2A, i.e., ACVR2A but not ACVR2B, as well as methods for using the same. The antibodies may be used for the treatment of a number of conditions associated with muscle atrophy, as well as other conditions.

ACVR2A-specific antibody and method of treatment of muscle atrophy

Provided herein are antigen binding molecules that bind to TIGIT, include antibodies and antigen binding fragments thereof.

Antigen binding molecules to TIGIT

Embodiments concern constructs comprising surrogate light chain sequences. In particular, embodiments concern constructs that can bind to ErbB3 and aspects relating to such constructs.

Sur-binding proteins against ERBB3

The present invention concerns the design and construction of diverse peptide and polypeptide libraries. In particular, the invention concerns methods of analytical database design for creating datasets using multiple relevant parameters as filters, and methods for generating sequence diversity by directed multisyntheses oligonucleotide synthesis. The present methods enable the reduction of large complex annotated databases to simpler datasets of related sequences, based upon relevant single or multiple key parameters that can be individually directly defined. The methods further enable the creation of diverse libraries based on this approach, using multisynthetic collections of discrete and degenerate oligonucleotides to capture the diverse collection of sequences, or portions thereof.

Construction of diverse synthetic peptide and polypeptide libraries

The invention concerns constructs and libraries comprising antibody surrogate light chain sequences. In particular, the invention concerns constructs comprising VpreB sequences, optionally partnered with another polypeptide, such as, for example, antibody heavy chain variable domain sequences, and libraries containing the same.

Constructs and libraries comprising antibody surrogate light chain sequences

The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza A virus subtypes, and methods and means for making such antibodies.

Neutralizing molecules to influenza viruses

Embodiments concern constructs comprising surrogate light chain sequences. In particular, embodiments concern constructs that can bind to DR4 and/or DR5 and aspects relating to such constructs and their use.

Surrogate binding proteins which bind DR4 and/or DR5

The present invention concerns methods and means for identifying, producing, and engineering neutralizing molecules against influenza A viruses, and to the neutralizing molecules produced. In particular, the invention concerns neutralizing molecules against various influenza A virus subtypes, including neutralizing antibodies against H5 and/or H3 and/or H1, such as, for example all of H1, H3, and H5 subtypes, and methods and means for making such molecules.

Neutralizing molecules to viral antigens

The present invention concerns surrogate light chain (SURROBODY&#x2122;) constructs comprising surrogate light chain sequences with heterologous signal sequences.

Expression of surrogate light chains

Methods and compositions directed to improved universal antibody libraries that rationally exploit human diversity information contained within reference antibody libraries, such as universal antibody libraries, are disclosed. The disclosed processes involve use of a query CDR sequence to guide incorporation of human antibody diversity present within the reference library into cohort libraries of the invention. Methods for making and screening such cohort libraries for isolating therapeutics suitable for treating disease are also disclosed.

Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening

The present invention concerns donor-specific antibody libraries derived from a patient donor who has suffered from, or is suffering from one or more diseases discussed herein. The present invention also concerns the method of making and using the donor-specific antibodies. The present invention further concerns the neutralizing antibodies obtained from the donor-specific antibody libraries and the methods of using these antibodies for the prevention/treatment of human disease.

Growing community of inventors

Belmont, CA, United States of America

Ramesh Bhatt